Sep 2026
A Platinum(IV)-Ursolic Acid Conjugate Overcomes Cisplatin Resistance in Ovarian Cancer by Targeting XPO1 and PARP1
Cisplatin is a cornerstone chemotherapeutic for ovarian cancer, yet its clinical utility is constrained by severe systemic toxicity and acquired drug resistance. Here we report a novel platinum (IV) prodrug, US-CIS-OH, generated by conjugating cisplatin with ursolic acid (UA), a natural pentacyclic triterpenoid with...
Zi-Qi Pan, Zhi-Ying Qin, Zi-Yu Qian et al.
· Journal of Medicinal Chemist... · 0 citations